Merck & Co., Inc. $MRK is Commonwealth Retirement Investments LLC’s 5th Largest Position

Commonwealth Retirement Investments LLC lessened its holdings in shares of Merck & Co., Inc. (NYSE:MRK) by 11.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 83,307 shares of the company’s stock after selling 10,599 shares during the quarter. Merck & Co., Inc. accounts for 2.9% of Commonwealth Retirement Investments LLC’s portfolio, making the stock its 5th largest position. Commonwealth Retirement Investments LLC’s holdings in Merck & Co., Inc. were worth $10,705,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of MRK. Brighton Jones LLC increased its stake in shares of Merck & Co., Inc. by 29.5% in the fourth quarter. Brighton Jones LLC now owns 38,278 shares of the company’s stock worth $3,808,000 after buying an additional 8,710 shares during the last quarter. Sivia Capital Partners LLC boosted its stake in Merck & Co., Inc. by 52.2% during the 2nd quarter. Sivia Capital Partners LLC now owns 11,494 shares of the company’s stock valued at $910,000 after acquiring an additional 3,941 shares during the last quarter. Diversify Advisory Services LLC grew its holdings in Merck & Co., Inc. by 94.1% during the 2nd quarter. Diversify Advisory Services LLC now owns 32,256 shares of the company’s stock worth $2,590,000 after acquiring an additional 15,636 shares in the last quarter. Diversify Wealth Management LLC grew its holdings in Merck & Co., Inc. by 22.2% during the 2nd quarter. Diversify Wealth Management LLC now owns 38,031 shares of the company’s stock worth $3,054,000 after acquiring an additional 6,897 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in Merck & Co., Inc. by 111.7% during the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 681,128 shares of the company’s stock worth $53,918,000 after acquiring an additional 359,356 shares in the last quarter. 76.07% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Merck & Co., Inc.

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Merck and Moderna reported that their individualized mRNA vaccine, used with Merck’s Keytruda, met the Phase 3 primary endpoint in high-risk melanoma. The combination improved recurrence-free survival and distant-metastasis-free survival compared with Keytruda alone, marking the first positive late-stage result for an mRNA cancer vaccine. The result could expand Merck’s oncology pipeline and help address the eventual loss of Keytruda exclusivity. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: Morgan Stanley upgraded MRK to overweight and raised its price target to $179 from $116, while UBS lifted its target to $175 and BMO raised its target to $170, reflecting increased confidence in the cancer-vaccine opportunity and Merck’s broader growth prospects. Merck upgraded at Morgan Stanley after cancer trial win; RBC downgrades
• Neutral Sentiment: Analysts cautioned that the initial results are not a complete regulatory or commercial victory. Full data, regulatory approval expected no earlier than 2027, manufacturing execution and the therapy’s eventual pricing and market adoption remain key uncertainties. Moderna’s Cancer Vaccine: Are Investors Putting The Cart Before The Horse?
• Negative Sentiment: RBC downgraded MRK to sector perform and set a $150 target, arguing that the roughly $150 valuation is unusually demanding for a company facing a major Keytruda loss of exclusivity in about two years. Jefferies also moved the stock to hold, creating a valuation overhang despite the trial success. Merck’s Cancer-Vaccine Trial Results Surpassed Expectations – So, Why Did RBC Downgrade MRK Stock?
• Negative Sentiment: Broader healthcare weakness and profit-taking after Merck’s sharp rally are adding pressure, while the stock’s elevated valuation leaves less room for disappointment. Sector Update: Healthcare Stocks Fall Thursday Afternoon

Insider Activity at Merck & Co., Inc.

In related news, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction that occurred on Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president directly owned 18,212 shares of the company’s stock, valued at $2,344,248.64. This represents a 50.67% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Jennifer Zachary sold 80,315 shares of the firm’s stock in a transaction on Wednesday, August 12th. The stock was sold at an average price of $133.46, for a total value of $10,718,839.90. Following the sale, the executive vice president directly owned 45,509 shares of the company’s stock, valued at approximately $6,073,631.14. This represents a 63.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 228,238 shares of company stock worth $29,977,783. Company insiders own 0.17% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages have issued reports on MRK. Weiss Ratings cut Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Morgan Stanley upgraded Merck & Co., Inc. from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $116.00 to $179.00 in a research report on Thursday. Argus boosted their price target on Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, August 11th. Wells Fargo & Company boosted their price target on Merck & Co., Inc. from $145.00 to $150.00 and gave the company an “overweight” rating in a report on Wednesday, July 8th. Finally, Scotiabank upped their price target on Merck & Co., Inc. from $136.00 to $155.00 and gave the company a “sector outperform” rating in a research report on Tuesday, June 30th. Fifteen investment analysts have rated the stock with a Buy rating and eight have given a Hold rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $142.10.

Merck & Co., Inc. Price Performance

NYSE MRK opened at $149.25 on Friday. The company has a 50-day moving average price of $127.43 and a two-hundred day moving average price of $121.01. Merck & Co., Inc. has a 52 week low of $77.58 and a 52 week high of $153.50. The stock has a market cap of $368.23 billion, a price-to-earnings ratio of 119.40, a price-to-earnings-growth ratio of 6.56 and a beta of 0.19. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share for the quarter, beating the consensus estimate of ($0.26) by $0.13. Merck & Co., Inc. had a return on equity of 16.73% and a net margin of 4.77%.The firm had revenue of $16.61 billion for the quarter, compared to the consensus estimate of $16.37 billion. During the same quarter in the previous year, the business earned $2.13 EPS. The firm’s revenue for the quarter was up 5.1% on a year-over-year basis. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Shareholders of record on Tuesday, September 15th will be issued a $0.85 dividend. This represents a $3.40 dividend on an annualized basis and a yield of 2.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Merck & Co., Inc.’s dividend payout ratio is presently 272.00%.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.